ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The contract research firm Evotec is joining the University of Oxford to create LAB282, a place where basic biomedical research from Oxford can be translated into preclinical proof of concept for new drugs and companies. Also participating are Oxford University Innovation, the school’s research commercialization arm, and Oxford Sciences Innovation, an investment company dedicated solely to Oxford. LAB282 will be supported by a $16 million investment fund. Projects will be aided by an Evotec drug discovery expert.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter